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Concentration and Synthesis of 
Phosphoribosylpyrophosphate in Erythrocytes From 
Normal, Hyperuricemic, and Gouty Subjects 
By FRANK L. MEYSKENS AND HIBBARD E. WILLIAMS 
Phosphoribosylpyrophosphate (PRPP) 
synthetase activity and the intracellular 
concentration of PRPP were assayed in 
erythrocytes from patients with primary 
hyperuricemia and primary metabolic 
gout. Sensitivity of the enzyme to feed- 
back inhibition by adenosine diphosphate 
(ADP), guanosine diphosphate (GDP), 
and 2,3-diphosphoglycerate (2,3-DPG) 
was determined. All patients with gout 
and four of ten patients with hyperuric- 
emia were taking ailopurinol during the 
study. Mean PRPP synthetase activity in 
erythrocytes from hyperuricemic and 
gouty patients was similar to that in nor- 
mal subjects, and feedback inhibition by 
ADP, GDP, and 2,3-DPG was intact. The 
concentration of PRPP in erythrocytes 
was higher in normal females than in 
normal males, higher in normal subjects 
than in gouty patients, and lower in hy- 
peruricemic patients taking allopurinol 
than in those hyperuricemic patients not 
taking this drug. The difference in intra- 
cellular levels of PRPP in erythrocytes in 
gout versus hyperuricemic patients was 
not significant. The significance of these 
findings is discussed in relation to the 
regulation of PRPP synthetase and in the 
important regulatory role of PRPP in 
purine metabolism. 
T HE INTRACELLULAR CONCENTRATION of 5-phosphoribosyl-1- pyrophosphate (PRPP) appears to be important in the regulation of 
purine metabolism. 1-4 Altered intracellular levels of PRPP have been reported 
in individuals with absence of the enzyme hypoxanthine-guanine phosphoribo- 
syltransferase (HGPRTase) 2,~ and in individuals with primary metabolic gout 
with normal HGPRTase levels. 2,6 Recently depletion of erythrocyte PRPP levels 
have been reported in hyperuricemic subjects given allopurinol, r Because ab- 
normal biosynthesis of PRPP might contribute to the pathogenesis of some cases 
of primary metabolic gout, the intracellular concentration of PRPP and the 
synthesis of PRPP and its regulation by feedback inhibition were studied in 
erythrocytes from normal subjects, patients with primary hyperuricemia, and 
patients with primary metabolic gout. 
MATERIALS AND METHODS 
Ten patients were considered to have primary hyperuricemia (mean age 49 yr) based on 
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serum uric acid concentrations (7.0-9.5 rag/100 ml) in the upper 2% of the population, 
normal creatinine clearance values, and no clinical evidence of gout, hematologic abnormali- 
ties, or malignant disease. Seven patients with primary metabolic gout (mean age 52 yr) had 
hyperuricemia of unknown origin and either a clinical history of gout or evidence of sub- 
cutaneous tophaceous deposits. Uric acid levels in the gouty patients ranged from 7.2-11.5 
rag/100 ml. Overproduction of uric acid was not established in these patients. Four of ten 
hyperuricemic patients and all gouty subjects were receiving allopurinol (dose range 100-400 
mg/day) during the study. The control group consisted of ten volunteers (mean age 28 yr) 
with serum uric acid concentrations within the normal range (3-6.0 mg/100 ml). All 
subjects had normal erythrocyte HGPRTase levels. 
Nonfasting blood samples were drawn by venipuncture into heparinized tubes and chilled 
(4~ immediately. The activity of PRPP synthetase was determined by the two-step ro- 
cedure o~ Hershko et al., using a charcoal-treated rythrocyte hemolysate in all assays. 1
Inhibition of PRPP synthetase by adenosine diphosphate (ADP), guanosine diphosphate 
(GDP), and 2,3-diphosphoglycerate (2,3-DPG) was determined by addition of these com- 
pounds to the reaction mixture at concentrations of 0.125, 0.125, and 5.0 mM, respectively. 
Inorganic phosphate (Pi) was maintained at a concentration of 5 mM, and an ATP- 
regenerating system was used in all assays. The formation of PRPP was found to be 
linear to enzyme concentration and time at the concentrations of ATP, Pi, and ribose-5- 
phosphate used. The concentration of PRPP was assayed by the method of Henderson and 
Khoo,S using bypoxanthine as substrate. This method is based on the observation that the 
concentration of PRPP is limiting in the conversion of hypoxanthine to inosinic acid by 
HGPRTase. Heparinized blood, chilled (4~ immediately and washed twice with two 
volmnes of 0.9% saline, was centrifuged at 10,000 g for 15 rain. Ethylenediaminetetraacetic 
acid (EDTA), 1.0 ml of 1 raM, was added to 1.0 ml of the packed ery-throcytes. The 
EDTA-stabilized mixture was then heated for 90 sec in boiling water and chilled (4~ 
immediately. 10% Norit A charcoal, 0.10 ml, was added to adsorb endogenous nucleotides. 
After mixing, the charcoal was deposited by centrifugation at 10,000 g for 10 min. Aliquots 
of the supernatant were assayed for PRPP using a dialyzed erythrocyte hemolysate with an 
HGPRTase activity of 100 m/tmoles/hr per mg protein. The HGPRTase activity was de- 
termined by the method of Kelley et al. 9 Radioactive hypoxanthine, inosine, and inosinic 
acid were separated by high voltage electrophoresis with a Savant Electrophorator (0.05 M 
borate buffer, pH 9.0, 3,000 V for 1 hr). Protein was determined by the method of Lowry 
et al. 10 
Reduced glutathione (GSH), adenosine triphospbate (ATP), ribose-5-phosphate (R5P), 
ADP, GDP, 2,3-DPG, phosphoenolpyruvate (PEP), and pyruvate kinase (PK) were pur- 
chased from Sigma Biochemical Co. Hypoxanthine-8-C14 (54.3 mCi/mmole) was purchased 
from New England Nuclear Corp. as the crystalline solid and was dissolved in distilled 
water prior to use to give a final concentration of 10/~Ci/ml. 
RESULTS 
The intracellular concentration of erythrocyte PRPP  varied among the dif- 
ferent groups studied (Table 1). Normal  subjects had a mean level of 3.03 • 
Table 1.--Concentration of PRPP in Ea'ythrocyles of. Normal Subjects and 
Hyperuricemic and Gouty Patients 
Erythrocyte PRPP Concentration* 
(m#moles/ml Packed Erythrocytes) 
Sex Normal Subjects Hyperuricemic Patients Gouty Patients 
Female 3.29 • 0.47 (5) 3.15 _+ 0.31 (3) 2.92 (1) 
Male 2.77 • 0.17 (5) 3.30 _ 0.55 (7) 2.26 - 0.40 (6) 
Mean 3.03 • 0.32 (10) 3.22 • 0.38 (10) 2.33 _ 0.39 (7) 
* Mean _ SD; numbers in parentheses are number of subjects. 
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Table 2.--PRPP Synthetase Activity in Erythrocyte Lysates and % Inhibition 
of Synthetase in Presence of ADP, GDP, and 2,3-DPG 
Synthetase Activity* % Synthetase Inhibition 
Subjects (m/xmoles/hr/mg protein) 0.125 rnM ADP 0.125 mM GDP 5.0 mM 2,3-DPG 
Normal 32.0 _ 5.3 72 64 80 
Hyperuricemic 32.7 _ 5.9 70 74 85 
Gouty 34.1 ___ 6.1 64 75 76 
* Mean +_ SD. 
0.32, hyperuricemic patients, 3.22 ----_ 0.38, and gouty patients, 2.33 • 0.39 
m~moles/ml packed erythrocytes. The difference in the concentration f PRPP 
in both the hyperuricemic and normal subjects compared with the levels of 
PRPP in gouty patients was significant at p < 0.05 (Student's t test). Normal 
female subjects had a higher level of erythrocyte PRPP than the normal males 
[3.29 4- 0.47 versus 2.77 --4- 0.17 m~moles/ml packed erythrocytes (p < 0.05)]. 
The mean erythrocyte PRPP level in the four hyperuricemic patients receiving 
allopurinol was 2.94 4- 0.29, compared with 3.47 _ 0.30 m~moles/ml packed 
erythrocytes in the six patients not taking the drug (p < 0.05). The effect of 
diet on PRPP levels was not determined in this study, although administration 
of large doses of both purines and pyrimidines have been shown to effect intra- 
cellular PRPP levels. 3,4 
The activity of PRPP synthetase in erythrocyte hemolysates from normal, 
hyperuricemic, and gouty subjects was 32.0 4- 5.3, 32.7 4- 5.9, and 34.7 4- 6.1 
m~moles/hr per mg protein, respectively. Inhibition of PRPP synthetase by 
ADP, GDP, and 2,3-DPG was similar in all three groups (Table 2). 
No correlation could be demonstrated between the concentration of erythro- 
cyte PRPP and the activity of PRPP synthetase. 
DISCUSSION 
Recent studies clearly demonstrate a partial deficiency of the enzyme 
HGPRTase in a small percentage of patients with primary metabolic gout. 9
In two patients evidence xists for an increase in uric acid production secondary 
to decreased feedback inhibition of the enzyme PRPP amidotransferase. 4 How- 
ever, the basic pathogenetic mechanisms operative in most cases of gout and 
hyperuricemia secondary to increased production of uric acid remain obscure. 
Recently, emphasis has been placed on the intracellular concentration f PRPP 
as an important factor controlling the production of uric acidY ,12 This com- 
pound is utilized at several sites in the synthetic pathways of purines and 
nucleotides (Fig. 1). An increase in PRPP synthesis leading to increased intra- 
cellular levels of this compound might result in increased production of purines. 
This is supported by the observation that intracellular levels of PRPP are well 
below the reported Km of this compound for the enzyme PRPP amidotransferase, 
the rate-limiting reaction in the de novo pathway for purine synthesis, la-~6 
The normal activity of PRPP synthetase observed in erythrocytes from hyper- 
uricemic and gouty patients uggests that the overproduction of uric acid in 
these patients is not due to an increase in PRPP formation secondary to an 
abnormality in this enzyme. Likewise, normal inhibition of erythrocyte PRPP 
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Fig 1.--Factors controlling intracellular PRPP concentration. 
synthetase by ADP, GDP, and 2,3-DPG suggests further that an increase in 
PRPP could not be afforded by this route. These studies do not rule out a defect 
in PRPP synthesis in other organs, since it was not possible to determine the 
activity of PRPP synthetase in other tissues from these subjects. There are no 
data at present o suggest hat this enzyme exists in isozymic forms, and the 
inhibition studies tend to confirm the similarity between the erythrocyte enzyme 
and that in other tissuesY q9 
The de novo synthesis of PRPP is controlled by the enzyme PRPP synthetase. 
Although studies of this enzyme are few, 1z-~9 the following characteristics have 
been noted: ATP and R5P are substrates, high levels of Pi and divalent cation 
(Mg ++ or Mn ++) are required, and a wide range of nucleotides inhibit the 
enzyme. Hershko et al. recently delineated the important role of P~ in human 
erythrocytes a a regulating factor in the expression of feedback inhibition and 
as an obligatory requirement before R5P levels become critical in the regulation 
of PRPP synthetase. 1 
The lack of correlation between PRPP levels and PRPP synthetase activity 
in the normal, hyperuricemic, and gouty subjects emphasizes the multitude of 
factors influencing intracellular PRPP concentrations (Fig. 1). An alteration in 
the hexose monophosphate shunt could provide excess R5P. An increased 
supply of R5P has been postulated to be a contributing factor in the hyper- 
uricemia ssociated with glycogen storage disease, type I. ~4 Hershko et al. noted 
an increased rate of formation of PRPP secondary to an elevated endogenous 
supply of R5P in some patients with gout. 2~ An increase in ribonucleoside break- 
down might provide excess R5P and might also increase purine catabolism. One 
study suggested that an alteration in glutathione r ductase may be important in 
the pathogenesis of some cases of gout. 21 
The levels of PRPP measured in erythrocytes agree well with those reported 
in other studies. 2,7 Although PRPP concentrations in erythrocytes from primary 
gout patients with normal HGPRTase levels were decreased, other authors found 
PRPP concentrations in cultured skin fibroblasts of some gout patients were 
elevated when compared with the values for normal subjects2 ,6 This difference 
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could be due to either the presence of a de novo pathway for purine synthesis 
in fibroblasts, or to an effect of allopurinol in the gouty and hyperuricemic pa- 
tients. The decreased levels of PRPP in erythrocytes in the gouty patients and 
in those hyperuricemic subjects taking allopurinol strongly suggest an effect of 
allopurinol on PRPP levels. Because all of the gouty subjects studied were 
taking allopurinol it is possible that the drug masked an abnormally elevated 
level of PRPP in this group. Preliminary investigation reveals that 1 mM allo- 
purinol in vitro does not inhibit PRPP synthetase activity in charcoal-treated 
erythrocyte lysates. 
Recently Fox et al. 7 demonstrated a significant depletion of erythrocyte PRPP 
levels in nine hyperuricemic patients given allopurinol. In this study no difference 
in erythrocyte PRPP concentration was found between hyperuricemic patients 
and normouricemic control subjects before allopurinol administration. These 
investigators also demonstrated a lowering of erythrocyte PRPP levels by allo- 
purinol when studied in vitro. In addition studies in vitro using erythrocyte 
lysates lacking HGPRTase activity indicated that neither allopurinol nor its 
ribonucleotide had an effect on PRPP synthesis. 
Although an alteration in PRPP synthetase activity in all subjects was not 
detected, the central role of PRPP in purine metabolism suggests that any 
alteration leading to the overproduction of PRPP might lead to overproduction 
of uric acid. The detection of an individual with an alteration in the metabolism 
of PRPP might greatly hasten and enhance the study of the regulation of PRPP 
and the elucidation of its role in purine metabolism. 
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